These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36621922)

  • 1. Hyperprolactinemia and insulin resistance.
    Gierach M; Bruska-Sikorska M; Rojek M; Junik R
    Endokrynol Pol; 2022; 73(6):959-967. PubMed ID: 36621922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy.
    Serri O; Li L; Mamputu JC; Beauchamp MC; Maingrette F; Renier G
    Clin Endocrinol (Oxf); 2006 Apr; 64(4):366-70. PubMed ID: 16584506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for an altered luteinizing hormone sensitivity to naloxone in pathological hyperprolactinaemia.
    Larrea F; Sandoval JL; Salinas E; Franco-Rodriguez VA; Méndez I; Ulloa-Aguirre A
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):591-600. PubMed ID: 8548944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels.
    Krysiak R; Okopien B
    Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):251-6. PubMed ID: 25123447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.
    Haddad PM; Wieck A
    Drugs; 2004; 64(20):2291-314. PubMed ID: 15456328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low prolactin levels are associated with visceral adipocyte hypertrophy and insulin resistance in humans.
    Ponce AJ; Galván-Salas T; Lerma-Alvarado RM; Ruiz-Herrera X; Hernández-Cortés T; Valencia-Jiménez R; Cárdenas-Rodríguez LE; Martínez de la Escalera G; Clapp C; Macotela Y
    Endocrine; 2020 Feb; 67(2):331-343. PubMed ID: 31919769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study.
    Krysiak R; Okrzesik J; Okopien B
    Endocrine; 2015 May; 49(1):242-9. PubMed ID: 25239203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of hyperprolactinemia and its control on metabolic diseases.
    Auriemma RS; De Alcubierre D; Pirchio R; Pivonello R; Colao A
    Expert Rev Endocrinol Metab; 2018 Mar; 13(2):99-106. PubMed ID: 30058862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of hyperprolactinaemia on Toxoplasma gondii prevalence in humans.
    Dzitko K; Malicki S; Komorowski J
    Parasitol Res; 2008 Mar; 102(4):723-9. PubMed ID: 18092180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic effects of prolactin.
    Pirchio R; Graziadio C; Colao A; Pivonello R; Auriemma RS
    Front Endocrinol (Lausanne); 2022; 13():1015520. PubMed ID: 36237192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists.
    Holt RI
    J Psychopharmacol; 2008 Mar; 22(2 Suppl):28-37. PubMed ID: 18477618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinctive features of prolactin secretion in acromegalic patients with hyperprolactinaemia.
    Serri O; Robert F; Comtois R; Jilwan N; Beauregard H; Hardy J; Somma M
    Clin Endocrinol (Oxf); 1987 Oct; 27(4):429-36. PubMed ID: 3124991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence of hyperprolactinaemia in subfertile ovulatory women and its impact on fertility treatment outcome.
    Wojcik M; Amer S; Jayaprakasan K
    J Obstet Gynaecol; 2022 Aug; 42(6):2349-2353. PubMed ID: 35473513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hyperprolactinaemia and bone mineral density].
    Kostrzak A; Męczekalski B
    Pol Merkur Lekarski; 2015 Aug; 39(230):122-5. PubMed ID: 26319389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses.
    Melkersson K; Berinder K; Hulting AL
    Neuro Endocrinol Lett; 2011; 32(4):428-36. PubMed ID: 21876517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Common endocrine disorders associated with the polycystic ovary syndrome.
    Abdelazim IA; Amer OO; Farghali M
    Prz Menopauzalny; 2020 Dec; 19(4):179-183. PubMed ID: 33488329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of hyperprolactinaemia with the use of the intervals for prolactin after macroforms separation.
    Beda-Maluga K; Pisarek H; Komorowski J; Swietoslawski J; Fuss-Chmielewska J; Winczyk K
    J Physiol Pharmacol; 2014 Jun; 65(3):359-64. PubMed ID: 24930507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperprolactinemia and insulin resistance in drug naive patients with early onset first episode psychosis.
    Petruzzelli MG; Margari M; Peschechera A; de Giambattista C; De Giacomo A; Matera E; Margari F
    BMC Psychiatry; 2018 Aug; 18(1):246. PubMed ID: 30068291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperprolactinaemia is common in Chinese premenopausal women with breast diseases.
    Zhu J; Tang Y; Lv C; Cong H; Liu J; Zhao S; Wang Y; Zhang K; Yu W; Cai Q; Ma R; Wang J
    Front Genet; 2023; 14():1018668. PubMed ID: 36845388
    [No Abstract]   [Full Text] [Related]  

  • 20. Hyperprolactinaemia and verapamil: prevalence and potential association with hypogonadism in men.
    Romeo JH; Dombrowski R; Kwak YS; Fuehrer S; Aron DC
    Clin Endocrinol (Oxf); 1996 Nov; 45(5):571-5. PubMed ID: 8977754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.